SINGLE-DOSE AND MULTIPLE-DOSE PHARMACOKINETICS OF AM-1155, A NEW 6-FLUORO-8-METHOXY QUINOLONE, IN HUMANS

被引:124
作者
NAKASHIMA, M
UEMATSU, T
KOSUGE, K
KUSAJIMA, H
OOIE, T
MASUDA, Y
ISHIDA, R
UCHIDA, H
机构
[1] KYORIN PHARMACEUT CO LTD, CENT RES LABS, NOGI, TOCHIGI 32901, JAPAN
[2] KYORIN PHARMACEUT CO LTD, TECH CTR PROD FORMULAT, NOGI, TOCHIGI 32901, JAPAN
[3] HAMAMATSU UNIV SCH MED, DEPT PHARMACOL, HAMAMATSU, SHIZUOKA 43131, JAPAN
关键词
D O I
10.1128/AAC.39.12.2635
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, was examined in healthy male volunteers after the oral administration of a single dose of 100, 200, 400, or 600 mg and multiple doses of 300 mg twice daily for 6.5 days (13 total doses). Throughout the whole study period, AM-1155 was well tolerated in every subject, In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 mu g/ml at the doses of 100, 200, 400, and 600 mg, respectively. The elimination half-life was 7 to 8 h, independently of the doses. The unchanged drug was excreted mainly in the urine, with 82 to 88% of the doses appearing for 72 h. The fecal recovery of the unchanged drug amounted to 5.7% for 72 h after a single oral administration of a 400-mg dose. Urinary excretion of metabolites was minimal, The serum protein binding was 20%, independently of the concentrations in serum, The concentrations in saliva were approximately 80% of those in serum, The intake of food had no effect on the pharmacokinetic parameters and urinary excretion of AM-1155 except the slight decrease in area under the concentration-time curve. The concurrent administration of probenecid prolonged the elimination half-life, increased the area under the concentration-time curve, and decreased the apparent total body clearance, renal clearance, urinary recovery of unchanged drug, and the excretion ratio (intrinsic renal clearance of AM-1155/creatinine clearance). This indicated that the tubular secretion contributed to the renal excretion of AM-1155. In the multiple-dose study, the concentrations of AM-1155 in serum and urine reached a steady state within 2 to 3 days. The measured concentrations in serum fitted well the simulation curve, which reflected the persistence of linear pharmacokinetics of AM-1155. In conclusion, AM-1155 is expected to be clinically useful because of its potent antibacterial activity and favorable pharmacokinetics.
引用
收藏
页码:2635 / 2640
页数:6
相关论文
共 27 条
[1]  
ABIKO T, 1981, CHEMOTHERAPY TOKY S4, V29, P136
[2]  
[Anonymous], 1984, CHEMOTHERAPY, V32, P118
[3]   PHARMACOKINETICS OF TEMAFLOXACIN IN HUMANS AFTER SINGLE ORAL DOSES [J].
GRANNEMAN, GR ;
CARPENTIER, P ;
MORRISON, PJ ;
PERNET, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) :436-441
[4]  
Hashimoto H., COMMUNICATION
[5]  
HIRAI K, 1993, DRUGS S3, V45, P182
[6]   INVITRO AND INVIVO ANTIBACTERIAL ACTIVITIES OF AM-1155, A NEW 6-FLUORO-8-METHOXY QUINOLONE [J].
HOSAKA, M ;
YASUE, T ;
FUKUDA, H ;
TOMIZAWA, H ;
AOYAMA, H ;
HIRAI, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (10) :2108-2117
[7]  
KAWAI M, 1984, CHEMOTHERAPY TOKY S3, V32, P334
[8]  
KOBAYASHI H, 1985, CHEMOTHERAPY TOKY S7, V33, P140
[9]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF 6,8-DIFLUORO-1-(2-FLUOROETHYL)-1,4-DIHYDRO-7-(4-METHYL-1-PIPERAZINYL)-4-OXO-3-QUINOLINECARBOXYLIC ACID AND ITS METABOLITES IN LABORATORY-ANIMALS [J].
KUSAJIMA, H ;
OOIE, T ;
KAWAHARA, F ;
UCHIDA, H .
JOURNAL OF CHROMATOGRAPHY, 1986, 381 (01) :137-148
[10]   CLINICAL PHARMACOKINETICS AND TOLERANCE OF FLEROXACIN IN HEALTHY MALE-VOLUNTEERS [J].
NAKASHIMA, M ;
KANAMARU, M ;
UEMATSU, T ;
TAKIGUCHI, A ;
MIZUNO, A ;
ITAYA, T ;
KAWAHARA, F ;
OOIE, T ;
SAITO, S ;
UCHIDA, H ;
MASUZAWA, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 :133-144